Comparison 2. Treatment failure.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall failure (disregarding modifications)	7	943	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.79, 1.27]
1.1 Glycopeptide empirical	3	293	Risk Ratio (M‐H, Fixed, 95% CI)	1.09 [0.28, 4.20]
1.2 Glycopeptide first modification	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	0.61 [0.18, 2.09]
1.3 Other antiGP empirical	3	485	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.81, 1.32]
2 Failure, modifications included	11	2169	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.65, 0.79]
2.1 Glycopeptide empirical	5	1178	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.61, 0.80]
2.2 Glycopeptide first modification	2	279	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.79, 1.22]
2.3 Other antiGP empirical	4	712	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.51, 0.77]
3 Failure, modifications included (adequate allocation concealment)	7	1101	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.68, 0.89]
3.1 Glycopeptide empirical	2	230	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.59, 1.08]
3.2 Glycopeptide first modification	2	279	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.79, 1.22]
3.3 Other antiGP empirical	3	592	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.53, 0.81]
4 Failure, modifications included (intention to treat)	7	1068	Risk Ratio (M‐H, Fixed, 95% CI)	0.79 [0.69, 0.90]
4.1 Glycopeptide empirical	2	186	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.61, 1.08]
4.2 Glycopeptide first modification	2	290	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.81, 1.23]
4.3 Other antiGP empirical	3	592	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.53, 0.81]
5 Failure, modifications included (antiGP not covering Gram‐negatives)	9	1659	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.69, 0.87]
5.1 Glycopeptide empirical	5	1178	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.61, 0.80]
5.2 Glycopeptide first modification	2	279	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.79, 1.22]
5.3 Other antiGP empirical	2	202	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.62, 1.67]
6 Failure in Gram‐positive infections	5	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.56 [0.38, 0.84]
7 Febrile at 72 hrs. on empirical Tx	3	312	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.44, 1.17]
7.1 Glycopeptide empirical	3	312	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.44, 1.17]
8 Addition of amphotericin	5	1201	Risk Ratio (M‐H, Random, 95% CI)	1.23 [0.84, 1.80]
8.1 Non‐blinded	3	976	Risk Ratio (M‐H, Random, 95% CI)	1.51 [0.80, 2.83]
8.2 Double blind	2	225	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.75, 1.33]